GAP-134

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

ArrhythmiaHealthy Subjects

Phase 1

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

CompletedNCT00510029

Wyeth is now a wholly owned subsidiary of PfizerArrhythmia

Start: 2007-09-30End: 2008-01-31Target: 72Updated: 2008-03-13

Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males

CompletedNCT00543946

Wyeth is now a wholly owned subsidiary of PfizerArrhythmia

Start: 2007-10-31End: 2008-03-31Updated: 2018-09-27

Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

CompletedNCT00783341

Wyeth is now a wholly owned subsidiary of PfizerHealthy Subjects

Start: 2008-11-30End: 2009-02-28Updated: 2009-07-17